

## GM-CSF, murine recombinant

### Information

|                                |   |
|--------------------------------|---|
| <b>Gene ID</b>                 | 12981   |
| <b>Accession #</b>             | P01587  |
| <b>Alternate Names</b>         | Granulocyte/Macrophage Colony-Stimulating Factor, CSF-2, MGI-1GM, Pluripoietin- $\alpha$  |
| <b>Source</b>                  | <i>Escherichia coli</i> .   |
| <b>M.Wt</b>                    | Recombinant murine GM-CSF is a 14.1 kDa globular protein consisting of 124 amino acids residues.  |
| <b>AA Sequence</b>             | APTRSPITVT RPWKHVEAIK EALNLLDDMP VTLNEEVEVV SNEFSFKKLT<br>CVQTRLKIFE QGLRGNFTKL KGALNMTASY YQTYCPPTPE TDCETQVTTY<br>ADFIDSLKTF LTDIPFECKK PGQK  |
| <b>Appearance</b>              | Sterile Filtered White lyophilized (freeze-dried) powder.   |
| <b>Stability &amp; Storage</b> | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.<br>- 12 months from date of receipt, -20 to -70 °C as supplied.<br>- 1 month, 2 to 8 °C under sterile conditions after reconstitution.<br>- 3 months, -20 to -70 °C under sterile conditions after reconstitution.  |
| <b>Formulation</b>             | Lyophilized from a 0.2 $\mu$ m filtered solution in PBS, pH 7.4.  |
| <b>Reconstitution</b>          | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at $\leq$ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| <b>Biological Activity</b>     | Fully biologically active when compared to standard. The ED <sub>50</sub> as determined by a cell proliferation assay using murine FDC-P1 cells is less than 0.05 ng/ml, corresponding to a specific activity of $> 2.0 \times 10^7$ IU/mg.   |
| <b>Shipping Condition</b>      | Gel pack.   |
| <b>Handling</b>                | Centrifuge the vial prior to opening.   |
| <b>Usage</b>                   | For Research Use Only! Not to be used in humans.  |

### Components and Storage

| Components                 | 5 $\mu$ g | 100 $\mu$ g | 500 $\mu$ g |
|----------------------------|-----------|-------------|-------------|
| GM-CSF, murine recombinant | 5 $\mu$ g | 100 $\mu$ g | 500 $\mu$ g |

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

## Quality Control

|           |   |
|-----------|---|
| Purity    | > 98 % by SDS-PAGE and HPLC analyses.                       |
| Endotoxin | Less than 1 EU/μg of rMuGM-CSF as determined by LAL method. |

## Description

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is secreted by a number of different cell types (including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts) in response to cytokine or immune and inflammatory stimulation. It was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors and has functions of stimulates the growth and differentiation of hematopoietic precursor cells from various lineages. GM-CSF has also been reported to have a functional role on non-hematopoietic cells and can induce human endothelial cells to migrate and proliferate. Additionally, it can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. Mouse GM-CSF shares 54 % sequences identity with human GM-CSF, but has no biological effects across species. GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy and has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients.

## Reference

1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3.
2. 1989. N Engl J Med, 320: 253-4.
3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101.
4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27.
5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31.

**APEx BIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)